Assessment of the Diagnostic Value of GFAP, IGFBP-2, and YKL-40 in Patients with Glioblastoma

Anahita  Ebrahimpour; Guive  Sharifi; Karimollah   Hajian-Tilaki; Shirin  Haghighifashi; Durdi  Qujeq

doi:10.18502/ijml.v8i2.6274

Anahita Ebrahimpour Student Research Committee, Babol University of Medical Sciences, Babol, Iran
Guive Sharifi Department of Neurosurgery, Loghman Hakim Hospital, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
Karimollah Hajian-Tilaki Department of Biostatistics and Epidemiology, Babol University of Medical Sciences, Babol, Iran
Shirin Haghighifashi Student Research Committee, Babol University of Medical Sciences, Babol, Iran
Durdi Qujeq Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

DOI: https://doi.org/10.18502/ijml.v8i2.6274

Keywords: Brain tumor, GFAP, Glioblastoma, IGFBP-2, YKL-40

Abstract

Background and Aims: An effective marker search in glioblastoma is precious in controlling and detecting the progression and monitoring of patients with glioblastoma. In this regard, the present study aimed to evaluate the diagnostic and prognostic role of glial fibrillary acidic protein (GFAP), insulin-like growth factor-binding protein -2 (IGFBP-2), and chitinase-3-like protein -1 (YKL-40) tissue and plasma levels in patients with GBM.

Materials and Methods: A total of 22 patients with newly diagnosed glioblastoma (the fourth grade of glioma) who had undergone surgery at the Erfan Hospital were included in the current study. The levels of GFAP, IGFBP-2 were evaluated in 22 tumor tissues, and non-timorous matched adjacent tissue samples of patients with glioblastoma using the enzyme-linked immunosorbent assay . Besides, 22 healthy subjects with no history of glioblastoma served as controls for plasma samples. All analyses were evaluated using the SPSS version 22.0.

Results: The tissue levels of GFAP, IGFBP-2, and YKL-40 were significantly higher in patients with glioblastoma when compared to the healthy controls (p=0.001). Nevertheless, there was no significant difference in comparison to the healthy control group in the plasma samples.

Conclusions: Tissue levels of GFAP, IGFBP-2, and YKL-40 may be potential biomarkers for predicting and the progression in patients with glioblastoma.